PRGO - Perrigo Company plc
| Previous Close | 76.42 |
| Open | 75.87 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 75.13 - 76.45 |
| 52 Week Range | 63.68 - 95.93 |
| Volume | 611,092 |
| Avg. Volume | 1,245,552 |
| Market Cap | 10.5B |
| Beta | 0.79 |
| PE Ratio (TTM) | 90.27 |
| EPS (TTM) | 0.84 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | 0.76 (1.00%) |
| Ex-Dividend Date | 2018-05-31 |
| 1y Target Est | 89.00 |
Market Realist•2 days agoS&P 500’s Top Gainers: Perrigo and Charles Schwab
The S&P 500’s top gainers on July 17 were: Perrigo (PRGO) gained 3.98%. Charles Schwab (SCHW) gained 3.56%. Johnson & Johnson (JNJ) gained 3.54%. Lam Research (LRCX) gained 3.17%. Aptiv (APTV) gained 2.98%. Perrigo
- Barrons.com•2 days ago
After the Bell: Dow Rises 56 Points as Stocks Keep Chugging Higher
Stocks notched another day of gains on Tuesday, on a day when there was little in the way of market-moving news. The Dow Jones Industrial Average gained 55.53 points, or 0.22%, to 25,119.89, while the S&P 500 is up 11.12 points, or 0.40%, to 2809.55 and the Nasdaq Composite added 49.40 points, or 0.63%, to 7855.12. Part of it may have been a "no news is good news," sort of mentality, as Federal Reserve Chief Jerome Powell's dry testimony before the Senate Banking Committee seemed to indicate that the Central Bank was committed to staying the course and markets largely shrugged off earnings reports on a relatively quiet day.
- Barrons.com•7 days ago
Drug Makers Can't Cure Investor Impatience
Shares of Johnson & Johnson (JNJ) have languished this year, but they're trading higher on Thursday, as Goldman Sachs argues that the worst may be over. Analyst Jami Rubin upgraded J&J to Neutral from Sell today, with a $134 price target. By contrast, she cut her rating on Perrigo (PRGO) to Sell from Neutral, and cut $4 from her price target, which now stands at $78.
- Benzinga•8 days ago
Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings
The iShares Dow Jones US Healthcare (ETF) (NYSE: IYH ) is up marginally year-to-date, but the profits aren’t bleeding into all health care constituents. The Ratings Goldman Sachs analyst Jami Rubin upgraded ...
Markit•17 days agoSee what the IHS Markit Score report has to say about Perrigo Company PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Reuters•20 days ago
AbbVie, AndroGel partner owe $448 million in antitrust case -U.S. judge
A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million. The ruling by U.S. District Judge Harvey Bartle in Philadelphia came in an antitrust lawsuit filed in 2014 by the Federal Trade Commission against AbbVie and its partner Besins Healthcare Inc.
Markit•24 days agoSee what the IHS Markit Score report has to say about Perrigo Company PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Reuters•25 days ago
Conviction of SAC's Martoma upheld despite jury instructions
A divided federal appeals court on Monday upheld the insider trading conviction of Mathew Martoma, a former portfolio manager for billionaire Steven A. Cohen, finding enough evidence to establish guilt despite defective jury instructions. It said the instructions wrongly allowed a conviction solely on evidence that a Michigan doctor had tipped Martoma about a Alzheimer's drug trial to maintain a friendship, rather than to offer a benefit or further a "quid pro quo" relationship.
- Simply Wall St.•28 days ago
Should You Buy Perrigo Company plc (NYSE:PRGO) Based On These Aspects?
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health toRead More...
- InvestorPlace•last month
Valeant Pharmaceuticals Intl Inc Has New Name But Same Problems
After June, you won’t have Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to kick around anymore. The Canada-based drug company is changing its name on Jul. 1 to Bausch Health Corp. That, along with the new ticker symbol (BHC), is supposed to put the company’s past behind it once and for all, leading to growth and profit for investors. Analysts are buying it. CEO Joseph Papa has fulfilled his promises to stop the rot, fix the balance sheet, and get the drug pipeline going again.
- Barrons.com•last month
Valeant & Perrigo: Buy One, Skip the Other
Barclays' Douglas Tsao takes a look at the specialty-pharmaceutical sector on Wednesday, upgrading Valeant Pharmaceuticals International (VRX) and downgrading Perrigo (PRGO). Taso boosted his rating on Valeant to Overweight, writing that his bullishness comes from his belief that the company's hit an inflection point, and the existing business has stabilized, leaving Valeant positioned to benefit from growth via new product launches. By contrast, he lowered is rating on Perrigo to Equal Weight, writing that the company's inability to win approval for its generic version of its inhaler ProAir "reduces near-term earnings momentum." Taso writes that management previously hoped for the treatment to continue nine cents to 2018 EPS, and even more in 2019, which now looks overly optimistic.
- GlobeNewswire•last month
Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners, Perrigo Company plc, Epizyme, and Landec — Future Expectations, Projections Moving into 2018
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Silicon ...
- TheStreet.com•2 months ago
Perrigo Stock Is Just Bearish, Any Way You Look At It
was downgraded to a sell today by TheStreet's Quant Ratings service. In this daily bar chart of PRGO, below, we can see that prices have been in a downtrend since its peak in late January. The daily On-Balance-Volume (OBV) line peaked back in November and has been trending lower since, signaling that sellers of PRGO have been and are more aggressive.
- ACCESSWIRE•2 months ago
Breakfast Technical Briefing on Johnson & Johnson and Three Other Additional Healthcare Stocks
Research reports have been issued by WallStEquities.com on Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Perrigo Co. PLC (NYSE: PRGO).
- PR Newswire•2 months ago
Perrigo to Present at the Jefferies 2018 Healthcare Conference
TASE: PRGO) today announced that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the Jefferies 2018 Healthcare Conference at 8:30 AM EST on Tuesday, June 5, 2018. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network.
- PR Newswire•2 months ago
Perrigo Confirms Patent Challenge For Generic Version Of Sernivo® Spray, 0.05%
TASE: PRGO) announced today that Promius Pharma LLC initiated patent litigation on May 22, 2018 in the U.S. District Court for the Eastern District of Texas, regarding Perrigo's Paragraph IV Abbreviated New Drug Application for betamethasone dipropionate, 0.05% spray, asserting patents listed in the Orange Book for Sernivo® Spray. Sernivo® (betamethasone dipropionate, 0.05%) Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older. Annual market sales for the 12 months ending March 2018 were approximately $16 million as measured by IQVIA. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®.
- Barrons.com•2 months ago
Starboard Value Buys $30.2 Million More in Perrigo Stock
Starboard Value disclosed that last week it bought $30.2 million in additional shares of Perrigo (PRGO), a maker of over-the-counter and generic drugs. Starboard now has total ownership of 10 million Perrigo shares, a stake of 7.3%, and is now that company's second-largest shareholder, according to S&P Capital IQ. The buying by Starboard seems to have been spurred by weakness after the company cut guidance.
- Benzinga•2 months ago
Benzinga's Insider Buys Of The Week: JPMorgan, Philip Morris And More
Insiders at a flooring products maker and a REIT returned to the buy window this week. Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and want to profit. Perrigo Company plc (NYSE: PRGO) saw one of its directors buy 400,000 shares of this Dublin-based health care products maker.
- Simply Wall St.•2 months ago
Is There An Opportunity With Perrigo Company plc’s (NYSE:PRGO) 30% Undervaluation?
Does the share price for Perrigo Company plc (NYSE:PRGO) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. If youRead More...
- Market Realist•2 months ago
Why Did Teva Stock Increase on May 14?
On May 14, Teva (TEVA) stock increased ~5.5% on the news of the expected delay in the FDA approval for rival Perrigo’s (PRGO) generic version of Teva’s asthma inhaler ProAir. On May 14, Teva stock closed at a trading price of $20.38 per share.
- Investor's Business Daily•2 months ago
Teva Pharma Spiked To Perrigo's Detriment On Asthma Inhaler Delay
Teva jumped Monday after competitor Perrigo said it expects the FDA to delay its generic version of Teva's asthma inhaler called ProAir.
- PR Newswire•2 months ago
Perrigo Confirms First To File Patent Challenge For Generic Version Of Ultravate® Lotion, 0.05%
TASE: PRGO) today announced that Sun Pharmaceutical Industries, Inc. and MiCal Pharmaceuticals LLC initiated patent litigations on May 9 and 10, 2018, in the U.S. District Court for the District of Delaware and in the U.S. District Court for the Western District of Michigan regarding Perrigo's Paragraph IV Abbreviated New Drug Application for halobetasol propionate lotion, 0.05% (a generic version of Ultravate® Lotion), asserting a patent listed in the Orange Book for Ultravate® Lotion. Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This first-to-file Paragraph IV ANDA is another example of making long-term investments in our extended topicals strategy. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®.
- The Wall Street Journal•2 months ago
Stocks to Watch: Tesla, Alphabet, Xerox, Sears, Qualcomm, NXP, Walmart, JPMorgan, Ford, HP
Stock movements reflect premarket trading. The electric auto maker has moved closer to setting up its first overseas car plant by registering a company in Shanghai. : Alphabet's Waymo LLC has hired a senior Tesla executive who was the auto maker's main technical contact with U.S. safety investigators.
- Barrons.com•2 months ago
Morning Movers: Qualcomm, NXP Jump as China Restarts Merger Review, Perrigo Drops on Drug Review
The Dow Jones Industrial Average appears set for a higher open this morning after President Donald Trump tweeted that he's working to get China's ZTE "back into business" following U.S. sanctions, a sign that a trade war might not be imminent. Dow Jones Industrial Average futures have risen 54 points, or 0.2%, while S&P 500 futures have ticked up 0.1%, and Nasdaq Composite futures have advanced 0.2%. Tigress Financials's Ivan Feinseth notes that not only is Trump working with China on ZTE, but that China has reopened an antitrust review of Qualcomm’s (QCOM) potential acquisition of NXP Semiconductor (NXPI).
